TABLE 1.
Differentially expressed exosomal miRNAs in ALS.
| Exosomal miRNA | Expression Level | Sample Type | Sample Size | Exosome Isolation Method | miRNA Detection Method | References |
| miR-124 | Up | NSC-34 Cells | NA | UC | qRT-PCR | Pinto et al., 2017 |
| miR-124a | Up | Astrocyte | NA | UC | qRT-PCR | Morel et al., 2013 |
| miR-124-3p | Up | CSF | 4 patients; 9 disease controls; 9 healthy controls | Total Exosome Isolation Reagent (Thermo Fisher) | qRT-PCR | Yelick et al., 2020 |
| miR-4736 | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4700-5p | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-1207-5p | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4739 | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4505 | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-24-3p | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-149-3p | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4484 | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4688 | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4298 | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-939-5p | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-371a-5p | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-3619-3p | Up | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4454 | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-9-1-5p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-9-3-5p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-338-3p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-9-2-5p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-100-5p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-7977 | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-1246 | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-664a-5p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-7641-1 | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-1290 | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-4286 | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-181b-1-5p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-1260b | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-181b-2-5p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-127-3p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-181a-2-5p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-181a-1-5p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-199a-2-3p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-199a-1-3p | Up | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-27a-3p | Down | Serum | 10 patients; 20 controls | ExoQuick and exoEasy Maxi Kit | qRT-PCR | Xu et al., 2018 |
| miR-1268a | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-2861 | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4508 | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4507 | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-3176 | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4745-5p | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-3911 | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-3605-5p | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-150-3p | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-3940-3p | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4646-5p | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR4687-5p | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4788 | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-4674 | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-1913 | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-634 | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-3177-3p | Down | Plasma | 5 patients; 5 healthy controls | Immuno-affinity | 3D-Gene chip | Katsu et al., 2019 |
| miR-532-3p | Down | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-144-3p | Down | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-15a-5p | Down | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-363-3p | Down | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| miR-183-5p | Down | Plasma | 14 patients; 8 healthy controls | Vn peptides | NGS | Saucier et al., 2019 |
| 101 significantly differentially expressed miRNA | − | Plasma | 10 patients; 10 healthy controls | ExoQuick (SBI) | NGS and qPCR | Banack et al., 2020 |